ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.
"Valeant's Oceanside unit has become an important division of our U.S. business with its successful launch and distribution of 5% fluorouracil, Valeant's authorized generic of Efudex®," stated J. Michael Pearson, chairman and chief executive officer. "Oceanside currently maintains a 55% market share of its Efudex® AG and plans to retain this leadership position in the future. With the industry experience we have had with Efudex® AG, we believe that we can successfully grow a strong market position with the launch of Librax® AG."
Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements, including, but not limited to, statements regarding Oceanside's launch and growth of Librax AG and Oceanside's strong leadership position with Efudex AG. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002 email@example.com
SOURCE Valeant Pharmaceuticals International
|Copyright©2009 PR Newswire.|
All rights reserved